Cover
Cover - shares | 6 Months Ended | |
Jun. 30, 2021 | Jul. 20, 2021 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jun. 30, 2021 | |
Document Transition Report | false | |
Entity File Number | 000-31141 | |
Entity Registrant Name | INFINITY PHARMACEUTICALS, INC. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 33-0655706 | |
Entity Address, Address Line One | 1100 Massachusetts Avenue | |
Entity Address, Address Line Two | Floor 4 | |
Entity Address, City or Town | Cambridge | |
Entity Address, State or Province | MA | |
Entity Address, Postal Zip Code | 02138 | |
City Area Code | 617 | |
Local Phone Number | 453-1000 | |
Title of 12(b) Security | Common Stock, $0.001 par value | |
Trading Symbol | INFI | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 88,719,539 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2021 | |
Document Fiscal Period Focus | Q2 | |
Entity Central Index Key | 0001113148 | |
Current Fiscal Year End Date | --12-31 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash and cash equivalents | $ 97,258 | $ 28,593 |
Available-for-sale securities | 0 | 5,515 |
Prepaid expenses and other current assets | 2,419 | 1,912 |
Total current assets | 99,677 | 36,020 |
Property and equipment, net | 1,471 | 1,710 |
Restricted cash, less current portion | 165 | 165 |
Operating lease right-of-use assets | 1,244 | 1,419 |
Other assets | 41 | 5 |
Total assets | 102,598 | 39,319 |
Current liabilities: | ||
Accounts payable | 954 | 2,982 |
Accrued expenses and other current liabilities | 9,600 | 8,065 |
Total current liabilities | 10,554 | 11,047 |
Liabilities related to sale of future royalties, net, less current portion (note 9) | 49,083 | 28,021 |
Liability related to sale of future royalties to a related party, net (note 9) | 0 | 21,559 |
Operating lease liability, less current portion | 1,188 | 1,436 |
Other liabilities | 233 | 245 |
Total liabilities | 61,058 | 62,308 |
Commitments and contingencies | ||
Stockholders’ equity (deficit): | ||
Preferred Stock, $0.001 par value; 1,000,000 shares authorized, no shares issued and outstanding at June 30, 2021 and December 31, 2020 | 0 | 0 |
Common Stock, $0.001 par value; 200,000,000 shares authorized; 88,719,539 and 64,320,244 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively | 89 | 64 |
Additional paid-in capital | 830,670 | 743,269 |
Accumulated deficit | (789,219) | (766,321) |
Accumulated other comprehensive income | 0 | (1) |
Total stockholders’ equity (deficit) | 41,540 | (22,989) |
Total liabilities and stockholders’ equity | $ 102,598 | $ 39,319 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares | Jun. 30, 2021 | Dec. 31, 2020 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 1,000,000 | 1,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 200,000,000 | 200,000,000 |
Common stock, shares issued (in shares) | 88,719,539 | 64,320,244 |
Common stock, shares outstanding (in shares) | 88,719,539 | 64,320,244 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Revenues: | ||||
Revenue, Product and Service | us-gaap:RoyaltyMember | |||
Total revenues | $ 512 | $ 360 | $ 979 | $ 788 |
Operating expenses: | ||||
Research and development | 7,957 | 6,125 | 16,158 | 13,470 |
General and administrative | 3,498 | 2,937 | 7,064 | 6,261 |
Royalty expense (note 11) | 308 | 217 | 590 | 475 |
Total operating expenses | 11,763 | 9,279 | 23,812 | 20,206 |
Loss from operations | (11,251) | (8,919) | (22,833) | (19,418) |
Other income (expense): | ||||
Investment and other income (expense) | 27 | 50 | 25 | 235 |
Non-cash interest expense (note 9) | (45) | (39) | (90) | (77) |
Non-cash related party interest expense (note 9) | 0 | (565) | 0 | (1,099) |
Total other expense | (18) | (554) | (65) | (941) |
Net loss | $ (11,269) | $ (9,473) | $ (22,898) | $ (20,359) |
Basic loss per common share (in dollars per share) | $ (0.13) | $ (0.16) | $ (0.28) | $ (0.35) |
Diluted loss per common share (in dollars per share) | $ (0.13) | $ (0.16) | $ (0.28) | $ (0.35) |
Basic weighted average number of common shares outstanding (in shares) | 88,661,934 | 57,442,332 | 82,230,784 | 57,392,965 |
Diluted weighted average number of common shares outstanding (in shares) | 88,661,934 | 57,442,332 | 82,230,784 | 57,392,965 |
Other comprehensive loss: | ||||
Net unrealized holding gains (losses) on available-for-sale securities arising during the period | $ 0 | $ (70) | $ 1 | $ 34 |
Comprehensive loss | $ (11,269) | $ (9,543) | $ (22,897) | $ (20,325) |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Operating activities | ||||
Net loss | $ (11,269) | $ (9,473) | $ (22,898) | $ (20,359) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||
Depreciation | 239 | 242 | ||
Stock-based compensation | 672 | 360 | 1,202 | 720 |
Non-cash royalty revenue | (518) | (417) | ||
Non-cash interest expense | 90 | 77 | ||
Non-cash related party interest expense | 0 | 1,099 | ||
Other, net | 24 | 25 | ||
Changes in operating assets and liabilities: | ||||
Prepaid expenses and other assets | (543) | 276 | ||
Operating lease right-of-use assets | 175 | 134 | ||
Accounts payable, accrued expenses and other liabilities | (571) | (906) | ||
Operating lease liability | (238) | (237) | ||
Net cash used in operating activities | (23,038) | (19,346) | ||
Investing activities | ||||
Purchases of property and equipment | 0 | (44) | ||
Purchases of available-for-sale securities | 0 | (19,731) | ||
Proceeds from maturities of available-for-sale securities | 5,500 | 26,180 | ||
Net cash provided by investing activities | 5,500 | 6,405 | ||
Financing activities | ||||
Proceeds from public offering, net | 85,838 | 0 | ||
Proceeds from sale of future royalties to a related party, net | 0 | 19,572 | ||
Proceeds from issuances of common stock, net | 365 | 30 | ||
Net cash provided by financing activities | 86,203 | 19,602 | ||
Net increase in cash, cash equivalents and restricted cash | 68,665 | 6,661 | ||
Cash, cash equivalents and restricted cash at beginning of period | 28,908 | 22,575 | ||
Cash, cash equivalents and restricted cash at end of period | 97,573 | 29,236 | 97,573 | 29,236 |
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets | ||||
Cash and cash equivalents | 97,258 | 28,921 | 97,258 | 28,921 |
Restricted cash included in prepaid expenses and other current assets | 150 | 0 | 150 | 0 |
Restricted cash, less current portion | 165 | 315 | 165 | 315 |
Total cash, cash equivalents and restricted cash | $ 97,573 | $ 29,236 | 97,573 | 29,236 |
Supplemental schedule of noncash activities | ||||
Issuance of common stock for compensation | $ 0 | $ 444 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Stockholders' Equity (Deficit) (unaudited) - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Accumulated Other Comprehensive Income (Loss) |
Beginning Balance (in shares) at Dec. 31, 2019 | 57,077,550 | ||||
Beginning Balance at Dec. 31, 2019 | $ 7,726 | $ 57 | $ 733,486 | $ (725,829) | $ 12 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Stock-based compensation expense | 720 | 720 | |||
Issuance of common stock, net (in shares) | 416,017 | ||||
Issuance of common stock, net | 495 | 495 | |||
Unrealized gain (loss) on marketable securities | 34 | 34 | |||
Net loss | (20,359) | (20,359) | |||
Ending Balance (in shares) at Jun. 30, 2020 | 57,493,567 | ||||
Ending Balance at Jun. 30, 2020 | (11,384) | $ 57 | 734,701 | (746,188) | 46 |
Beginning Balance (in shares) at Mar. 31, 2020 | 57,433,598 | ||||
Beginning Balance at Mar. 31, 2020 | (2,252) | $ 57 | 734,290 | (736,715) | 116 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Stock-based compensation expense | 360 | 360 | |||
Issuance of common stock, net (in shares) | 59,969 | ||||
Issuance of common stock, net | 51 | 51 | |||
Unrealized gain (loss) on marketable securities | (70) | (70) | |||
Net loss | (9,473) | (9,473) | |||
Ending Balance (in shares) at Jun. 30, 2020 | 57,493,567 | ||||
Ending Balance at Jun. 30, 2020 | (11,384) | $ 57 | 734,701 | (746,188) | 46 |
Beginning Balance (in shares) at Dec. 31, 2020 | 64,320,244 | ||||
Beginning Balance at Dec. 31, 2020 | (22,989) | $ 64 | 743,269 | (766,321) | (1) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Exercise of stock options (in shares) | 206,491 | ||||
Exercise of stock options | 336 | $ 1 | 335 | ||
Stock-based compensation expense | 1,202 | 1,202 | |||
Issuance of common stock related to public offering, net of issuance costs (in shares) | 24,150,000 | ||||
Issuance of common stock related to public offering, net of issuance costs | 85,838 | $ 24 | 85,814 | ||
Issuance of common stock, net (in shares) | 42,804 | ||||
Issuance of common stock, net | 50 | 50 | |||
Unrealized gain (loss) on marketable securities | 1 | 1 | |||
Net loss | (22,898) | (22,898) | |||
Ending Balance (in shares) at Jun. 30, 2021 | 88,719,539 | ||||
Ending Balance at Jun. 30, 2021 | 41,540 | $ 89 | 830,670 | (789,219) | 0 |
Beginning Balance (in shares) at Mar. 31, 2021 | 88,647,241 | ||||
Beginning Balance at Mar. 31, 2021 | 52,046 | $ 89 | 829,907 | (777,950) | 0 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Exercise of stock options (in shares) | 29,494 | ||||
Exercise of stock options | 41 | $ 0 | 41 | ||
Stock-based compensation expense | 672 | 672 | |||
Issuance of common stock, net (in shares) | 42,804 | ||||
Issuance of common stock, net | 50 | 50 | |||
Unrealized gain (loss) on marketable securities | 0 | ||||
Net loss | (11,269) | (11,269) | |||
Ending Balance (in shares) at Jun. 30, 2021 | 88,719,539 | ||||
Ending Balance at Jun. 30, 2021 | $ 41,540 | $ 89 | $ 830,670 | $ (789,219) | $ 0 |
Organization
Organization | 6 Months Ended |
Jun. 30, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization | 1. Organization Infinity Pharmaceuticals, Inc., is a clinical-stage innovative biopharmaceutical company dedicated to developing novel medicines for people with cancer. As used throughout these unaudited, condensed consolidated financial statements, the terms “Infinity,” “we,” “us,” and “our” refer to the business of Infinity Pharmaceuticals, Inc., and its wholly-owned subsidiaries. |
Basis of Presentation
Basis of Presentation | 6 Months Ended |
Jun. 30, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of Presentation | 2. Basis of Presentation These condensed consolidated financial statements include the accounts of Infinity and its wholly-owned subsidiaries. We have eliminated all significant intercompany accounts and transactions in consolidation. The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the accompanying condensed consolidated financial statements have been included. Interim results for the three and six months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2021. The information presented in the condensed consolidated financial statements and related footnotes at June 30, 2021, and for the three and six months ended June 30, 2021 and 2020, is unaudited, and the condensed consolidated balance sheet amounts and related footnotes at December 31, 2020 have been derived from our audited financial statements. For further information, please refer to the consolidated financial statements and accompanying footnotes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission, or SEC, on March 16, 2021, which we refer to as our 2020 Annual Report on Form 10-K. Liquidity As of June 30, 2021, we had cash and cash equivalents of $97.3 million. We have primarily incurred operating losses since inception and have relied on our ability to fund our operations through collaboration and license arrangements or other strategic arrangements, as well as through the sale of stock. We expect to continue to spend significant resources to fund the development and potential commercialization of eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma, or PI3K-gamma, and to incur significant operating losses for the foreseeable future. We believe that our existing cash and cash equivalents at June 30, 2021 will be adequate to satisfy our forecasted operating needs for at least the next twelve months from the issuance date of these financial statements. |
Significant Accounting Policies
Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2021 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies | 3. Significant Accounting Policies Our significant accounting policies are described in Note 2, “Summary of Significant Accounting Policies,” in “Notes to Consolidated Financial Statements” in our 2020 Annual Report on Form 10-K. Segment Information We operate in one business segment, which focuses on drug development. We make operating decisions based upon the performance of the enterprise as a whole and utilize our consolidated financial statements for decision making. Basic and Diluted Net Loss per Common Share Basic net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted net loss per share is based upon the weighted average number of common shares outstanding during the period plus the effect of additional weighted average common equivalent shares outstanding during the period when the effect of adding such shares is dilutive. Common equivalent shares result from the assumed exercise of outstanding stock options and the exercise of outstanding warrants (the proceeds of which are then assumed to have been used to repurchase outstanding stock using the treasury stock method). In addition, the assumed proceeds under the treasury stock method include the average unrecognized compensation expense of stock options that are in-the-money. This results in the “assumed” buyback of additional shares, thereby reducing the dilutive impact of stock options. The two-class method is used for outstanding warrants as such warrants are considered to be participating securities, and this method is more dilutive than the treasury stock method. The following outstanding shares of common stock equivalents were excluded from the computation of net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: At June 30, 2021 2020 Stock options 12,583,847 11,108,447 Warrants (excluded from treasury stock method) — 1,000,000 New Accounting Pronouncements In June 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standard Update, or ASU, No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements, or ASU No. 2016-13, which requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and it establishes additional disclosure requirements related to credit risks. For available-for-sale debt securities with expected credit losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. In November 2019, the FASB subsequently issued ASU 2019-10, Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates, whereby the effective date of this standard for smaller reporting companies was deferred to annual reporting periods beginning after December 15, 2022, including interim periods within those annual reporting periods, and early adoption is still permitted. We are currently evaluating the impact of ASU No. 2016-13 on our consolidated financial statements and related disclosures. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, or ASU No. 2020-06, which simplifies the guidance on an issuer’s accounting for convertible instruments and contracts in its own equity. The provisions of ASU No. 2020-06 are applicable for fiscal years beginning after December 15, 2023, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. We are currently evaluating the impact of ASU No. 2020-06 on our consolidated financial statements. |
Stock-Based Compensation
Stock-Based Compensation | 6 Months Ended |
Jun. 30, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Stock-Based Compensation | 4. Stock-Based Compensation Total stock-based compensation expense related to all equity awards for the three and six months ended June 30, 2021 and 2020 was composed of the following: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 (in thousands) Research and development $ 165 $ 94 $ 316 $ 174 General and administrative 507 266 886 546 Total stock-based compensation expense $ 672 $ 360 $ 1,202 $ 720 As of June 30, 2021, we had approximately $5.1 million of total unrecognized compensation cost related to unvested common stock options and awards under our Employee Stock Purchase Plan, which is expected to be recognized over a weighted-average period of 2.8 years. Stock Options During the six months ended June 30, 2021, we granted options to purchase 289,040 shares of our common stock at a weighted average fair value of $2.68 per share and a weighted average exercise price of $3.37 per share. During the six months ended June 30, 2020, we granted options to purchase 3,148,786 shares of our common stock at a weighted average fair value of $0.89 per share and a weighted average exercise price of $1.17 per share. For the three and six months ended June 30, 2021 and 2020, the fair values were estimated using the Black-Scholes valuation model using the following weighted-average assumptions: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Risk-free interest rate 0.8 % 0.3 % 0.9 % 1.4 % Expected annual dividend yield — — — — Expected stock price volatility 106.5 % 101.6 % 105.5 % 98.2 % Expected term of options 5.5 years 4.1 years 5.6 years 5.6 years |
Cash, Cash Equivalents and Avai
Cash, Cash Equivalents and Available-for-Sale Securities | 6 Months Ended |
Jun. 30, 2021 | |
Cash and Cash Equivalents [Abstract] | |
Cash, Cash Equivalents and Available-for-Sale Securities | 5. Cash, Cash Equivalents and Available-for-Sale Securities The following is a summary of cash, cash equivalents and available-for-sale securities: June 30, 2021 Cost Gross Gross Estimated (in thousands) Cash and cash equivalents $ 97,258 $ — $ — $ 97,258 Total cash and cash equivalents $ 97,258 $ — $ — $ 97,258 December 31, 2020 Cost Gross Gross Estimated (in thousands) Cash and cash equivalents $ 28,593 $ — $ — $ 28,593 Available-for-sale securities: U.S. Treasury securities due in one year or less 5,516 — (1) 5,515 Total available-for-sale securities 5,516 — (1) 5,515 Total cash, cash equivalents and available-for-sale securities $ 34,109 $ — $ (1) $ 34,108 We evaluated our securities for other-than-temporary impairments based on quantitative and qualitative factors. We did not hold any debt securities at June 30, 2021 that were in an unrealized loss position. As of June 30, 2021, we held no securities in foreign financial institutions. We had no material realized gains or losses on our available-for-sale securities for the three and six months ended June 30, 2021 and 2020. There were no other-than-temporary impairments recognized for the three and six months ended June 30, 2021 and 2020. |
Fair Value
Fair Value | 6 Months Ended |
Jun. 30, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value | 6. Fair Value The following table presents the assets and liabilities carried at fair value measured on a recurring basis as of June 30, 2021 and December 31, 2020: June 30, 2021 Level 1 Level 2 Level 3 (in thousands) Assets: Cash and cash equivalents $ 97,258 $ — $ — Total assets $ 97,258 $ — $ — Liabilities: Warrant liability $ — $ — $ 185 Total liabilities $ — $ — $ 185 December 31, 2020 Level 1 Level 2 Level 3 (in thousands) Assets: Cash and cash equivalents $ 28,593 $ — $ — U.S. Treasury securities — 5,515 — Total assets $ 28,593 $ 5,515 $ — Liabilities: Warrant liability $ — $ — $ 198 Total liabilities $ — $ — $ 198 The fair value of the available-for-sale securities and cash and cash equivalents is based on the following inputs for both U.S. Treasury securities and U.S. government-sponsored enterprise obligations: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including TRACE ® reported trades. There have been no changes to our valuation methods of available-for-sale securities during the six months ended June 30, 2021. We had no available-for-sale securities that were classified as Level 3 at any point during the six months ended June 30, 2021 or during the year ended December 31, 2020. Warrant liability relates to potential future warrants that may be issued. The fair value of the warrant liability on the date of the commitment and on each re-measurement date for those warrants classified as liabilities was estimated using the Monte Carlo simulation model, which involves a series of simulated future stock price paths over the remaining life of the commitment. The fair value is estimated by taking the average of the fair values under each of many Monte Carlo simulations. The fair value estimate is affected by our stock price, as well as estimated future financing needs, including timing and sources of the financing and subjective variables including expected stock price volatility over the remaining life of the commitment and risk-free interest rate. Due to the nature of these inputs, the valuation of the warrants is considered a Level 3 measurement. The fair value of the warrant liability as of June 30, 2021 and December 31, 2020 has been included in other liabilities on our condensed consolidated balance sheet. See Note 9 for further discussion of the accounting for the warrants. The carrying amounts reflected in the condensed consolidated balance sheets for prepaid expenses and other current assets, other assets, accounts payable and accrued expenses approximate their fair value due to their short-term maturities. |
Prepaid Expenses and Other Curr
Prepaid Expenses and Other Current Assets | 6 Months Ended |
Jun. 30, 2021 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |
Prepaid Expenses and Other Current Assets | 7. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following: June 30, 2021 December 31, 2020 (in thousands) Prepaid expenses $ 2,026 $ 1,528 Restricted cash, current portion 150 150 Other current assets 243 234 Total prepaid expenses and other current assets $ 2,419 $ 1,912 |
Accrued Expenses and Other Curr
Accrued Expenses and Other Current Liabilities | 6 Months Ended |
Jun. 30, 2021 | |
Payables and Accruals [Abstract] | |
Accrued Expenses and Other Current Liabilities | 8. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: June 30, 2021 December 31, 2020 (in thousands) Accrued clinical and development $ 5,404 $ 3,511 Accrued compensation and benefits 1,667 2,385 Liability related to sale of future royalties, net, current portion 917 848 Operating lease liability, current portion 500 489 Other 1,112 832 Total accrued expenses $ 9,600 $ 8,065 |
Liabilities Related to Sale of
Liabilities Related to Sale of Future Royalties | 6 Months Ended |
Jun. 30, 2021 | |
Debt Disclosure [Abstract] | |
Liabilities Related to Sale of Future Royalties | 9. Liabilities Related to Sale of Future Royalties HCR Agreement In 2016, we and Verastem Inc., or Verastem, entered into an amended and restated license agreement, or the Verastem Agreement, under which we granted to Verastem an exclusive worldwide license in oncology indications for the research, development, commercialization, and manufacture of duvelisib, or Copiktra ® , an oral, dual inhibitor of PI3K delta and gamma, and products containing duvelisib, which we refer to as Licensed Products. In September 2020, Verastem completed a disposition of its rights, title, and interest in and to duvelisib to Secura Bio, Inc., or Secura Bio, whereby Secura Bio assumed all liabilities and obligations under the Verastem Agreement. We now refer to the Verastem Agreement as the Secura Bio Agreement. Secura Bio is obligated to pay us royalties on worldwide net sales of Licensed Products ranging from the mid-single digits to the high-single digits, a portion of which we are obligated to share with Takeda Pharmaceuticals Company Limited, or Takeda, as described in Note 11. In March 2019, we entered into a royalty purchase agreement, or the HCR Agreement, with HealthCare Royalty Partners III, L.P., or HCR, providing for the acquisition by HCR of our interest in certain royalty payments based on worldwide annual net sales of Licensed Products under the Secura Bio Agreement for gross proceeds of $30.0 million, which is non-refundable. Under the HCR Agreement, HCR obtained the right to receive the royalty payments up to agreed upon thresholds of royalties, the amount of which depends on when the aggregate royalties received by HCR reach specified thresholds. If the specified threshold has been met through royalty payments from Secura Bio or if we elect to make a payment to meet the threshold amount, the HCR Agreement will automatically terminate and all rights to the royalty stream under the HCR Agreement will revert back to us. If the specified threshold has not been achieved by June 30, 2025, the HCR Agreement will continue through the term of the Secura Bio Agreement. We recognized the receipt of the $30.0 million payment from HCR, net of debt discount and issuance costs of approximately $2.4 million, as a liability. As the basis for our determination, we considered, in accordance with the relevant accounting guidance, the potential for the royalty stream to revert back to us if specified royalty thresholds have been met and our right to terminate the HCR Agreement by making a payment to achieve the threshold. We are not obligated to repay the proceeds received under the HCR Agreement. In order to determine the amortization of the liability, we are required to estimate the total amount of future net royalty payments to be made to HCR over the term of the HCR Agreement. The total threshold of net royalties to be paid, less the net proceeds received, will be recorded as interest expense over the life of the liability. We impute interest on the unamortized portion of the liability using the effective interest method. Interest and debt discount amortization expense is reflected as non-cash interest expense in the condensed consolidated statements of operations. Over the course of the HCR Agreement, the actual interest rate will be affected by the amount and timing of royalty revenue recognized and changes in forecasted royalty revenue. On a quarterly basis, we reassess the effective interest rate and adjust the rate prospectively as needed. The following table shows the activity within the liability account for the six months ended June 30, 2021: June 30, 2021 (in thousands) Liability related to sale of future royalties, net - beginning balance $ 28,869 Non-cash royalty revenue (518) Non-cash interest expense recognized 77 Liability related to sale of future royalties, net - ending balance 28,428 Less: current portion (917) Liability related to sale of future royalties, net, less current portion $ 27,511 As royalties are due to HCR by Secura Bio, the balance of the recognized liability will be effectively repaid over the life of the HCR Agreement. There are a number of factors that could materially affect the amount and timing of royalty payments from Secura Bio, none of which are within our control. BVF Agreement On January 8, 2020, or the BVF Closing Date, we entered into a funding agreement, or the BVF Funding Agreement, with BVF Partners, L.P., or BVF, and Royalty Security, LLC, a wholly-owned subsidiary of BVF, or the Buyer. BVF was subsequently replaced as a party to the BVF Funding Agreement with Royalty Security Holdings, LLC. The BVF Funding Agreement provides for the acquisition by the Buyer of our interest in all royalty payments based on worldwide annual net sales of a clinical-stage product candidate IPI-926, or patidegib, part of the hedgehog inhibitor program we licensed to PellePharm Inc., or PellePharm, in 2013, or the BVF Licensed Product, excluding relevant Trailing Mundipharma Royalties, as defined in Note 11, which is related to patidegib. We refer to all BVF Licensed Product royalties owed to us less Trailing Mundipharma Royalties as the Royalty or Royalties. Such Royalties are owed to us pursuant to the PellePharm Agreement, as defined in Note 11, entered into by and between us and PellePharm. The Buyer and BVF are affiliates of Biotechnology Value Fund, L.P., which beneficially owned approximately 30% of our common stock at the time of the transaction. Effective February 17, 2021, Biotechnology Value Fund, L.P. is no longer considered our related party. Pursuant to the BVF Funding Agreement, we received a non-refundable payment of $20.0 million, or the Upfront Purchase Price, less certain transaction expenses. We transferred to the Buyer (i) the Royalty, (ii) the PellePharm Agreement (subject to our rights to milestone payments and rights to equity in PellePharm under the PellePharm Agreement), and (iii) certain patent rights established in the BVF Funding Agreement, with (i), (ii), and (iii) together referred to as Transferred Assets. We preserved our rights under the PellePharm Agreement to receive potential regulatory, commercial, and success-based milestone payments. We have the option to terminate the BVF Funding Agreement by purchasing 100% of the outstanding equity interests of the Buyer under specified terms for a specified amount under the BVF Funding Agreement through January 8, 2023. In addition, the BVF Funding Agreement may be terminated by mutual written agreement of us and the Buyer. We recognized the proceeds received under the BVF Funding Agreement as a related party liability that will be amortized using the effective interest method over the life of the arrangement. We recorded the receipt of the $20.0 million Upfront Purchase Price as a liability, net of debt issuance costs of approximately $0.4 million and warrant liability of $0.3 million. The related party liability has been reclassified to liabilities related to sale of future royalties since Biotechnology Value Fund, L.P. is no longer considered our related party. We are not obligated to repay the proceeds received under the BVF Funding Agreement. In order to determine the amortization of the liability, we are required to estimate the total amount of potential future net royalty payments to be made by PellePharm to the Buyer over the term of the BVF Funding Agreement. The total estimated net royalties to be paid, less the net proceeds received, will be recorded as interest expense over the life of the liability. Interest and debt discount amortization expense is reflected as non-cash related party interest expense as of December 31, 2020 and non-cash interest expense as of June 30, 2021 in our condensed consolidated statements of operations and comprehensive loss. Over the course of the BVF Funding Agreement, the actual interest rate will be affected by the amount and timing of royalty revenue recognized, if any, and changes in forecasted royalty revenue. There are a number of factors that could materially affect the amount and timing of royalty payments from PellePharm, none of which are within our control. On a quarterly basis, we will reassess the effective interest rate and adjust the rate prospectively as needed. The following table shows the activity within the liability account for the six months ended June 30, 2021: June 30, 2021 (in thousands) Liability related to sale of future royalties, net - beginning balance $ 21,559 Non-cash interest expense recognized 13 Liability related to sale of future royalties, net - ending balance $ 21,572 For so long as we have not exercised an option to repurchase the Buyer’s equity interest under the BVF Funding Agreement, (a) if, during the 36-month period following the BVF Closing Date, we issue a specified number of shares of our common stock, which we refer to as the Warrant Threshold, and (b) any shares in excess of the Warrant Threshold are issued for consideration to us of less than $3.75 per share (as adjusted for any stock splits, reverse stock splits or other similar recapitalization events), or the Threshold Price, then we are obligated to issue to BVF warrants to purchase a number of shares of our common stock. Such warrants would equal 50% of the number of qualifying shares at an exercise price equal to 1.5 times the price per share of such qualifying shares issued. The requirement to issue warrants to BVF does not apply to certain issuances of our common stock. As of June 30, 2021, the Warrant Threshold has been met and any future qualifying shares of our common stock issued below the Price Threshold will result in warrants to purchase our common stock to be issued to BVF. No warrants have been issued to BVF as of June 30, 2021. We determined that the commitment to issue warrants represents a freestanding financial instrument and accounted for it as a liability as of the BVF Closing Date. The fair value of the warrant liability was estimated using the Monte Carlo simulation model. The fair value of the warrant liability as of June 30, 2021 has been included in other liabilities on our condensed consolidated balance sheet. We will re-measure the warrant liability at each reporting date. Changes in fair value of the warrant liability are included in investment and other income (expense) in our condensed consolidated statements of operations and comprehensive loss. See Note 6 for further discussions of the fair value of the warrants. |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2021 | |
Leases [Abstract] | |
Commitments and Contingencies | 10. Commitments and Contingencies On April 5, 2019, we entered into a lease agreement, or the Lease, with Sun Life Assurance Company of Canada, or the Landlord, effective April 3, 2019, or the Commencement Date, for the lease of approximately 10,097 square feet of office space at 1100 Massachusetts Avenue, Cambridge, Massachusetts, or the Leased Premises. The term of the Lease commenced on the Commencement Date and expires on August 1, 2024, or the Expiration Date, approximately five years after the Rent Commencement Date as defined below. Beginning August 1, 2019, or the Rent Commencement Date, the total base rent of the Lease was $47,961 per month and increases by approximately 3% on each anniversary of the Rent Commencement Date until the Expiration Date. In addition to the base rent, we are also responsible for our share of the operating expenses, insurance, real estate taxes and certain capital costs, and we are responsible for utility expenses in the Leased Premises, all in accordance with the terms of the Lease. Pursuant to the terms of the Lease, we provided a security deposit in the form of a letter of credit in the initial amount $300,000, which may be reduced to $150,000 over time in accordance with the terms of the Lease. The current portion of the security deposit is included on our condensed consolidated balance sheet as prepaid expenses and other current assets. The remaining portion plus the associated bank fee of $15,000 is included on our condensed consolidated balance sheet as restricted cash, less current portion as of June 30, 2021. The Landlord provided a lease incentive allowance of $0.6 million to fund certain improvements to be made by us to the Leased Premises. |
Strategic Agreements
Strategic Agreements | 6 Months Ended |
Jun. 30, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Strategic Agreements | 11. Strategic Agreements We have worldwide development and commercialization rights to eganelisib, subject to certain obligations to our licensor, Takeda Pharmaceutical Company Limited, or Takeda, as described in more detail below. Additionally, we are obligated to pay Mundipharma International Corporation Limited, or Mundipharma, and Purdue Pharmaceutical Products L.P., or Purdue, a 4% royalty in the aggregate on worldwide net sales of products that were previously subject to our strategic alliance with Mundipharma and Purdue that was terminated in 2012. Such products include eganelisib; duvelisib, the PI3K delta,gamma inhibitor we licensed to Verastem, in 2016, and Verastem sold its interest in these rights to Secura Bio in 2020; and IPI-926, or patidegib, part of the hedgehog inhibitor program we licensed to PellePharm in 2013. We refer to such royalties as Trailing Mundipharma Royalties. After Mundipharma and Purdue have recovered approximately $260.0 million in royalty payments from all products that were previously subject to the strategic alliance, which represents the funding paid to us for research and development services performed by us under this strategic alliance, the Trailing Mundipharma Royalties will be reduced to a 1% royalty on net sales in the United States of such products. PellePharm In June 2013, we entered into a license agreement with PellePharm, under which we granted PellePharm exclusive global development and commercialization rights to our hedgehog inhibitor program, including patidegib. We refer to our license agreement with PellePharm as the PellePharm Agreement and products covered by the PellePharm Agreement as Hedgehog Products. We assessed this arrangement in accordance with Accounting Standard Codification 606 and concluded that at the date of contract inception there was only one performance obligation, consisting of the license, which was satisfied at contract inception. Under the PellePharm Agreement, PellePharm is obligated to pay us up to $9.0 million in remaining regulatory and commercial-based milestone payments through the first commercial sale of a Hedgehog Product. PellePharm is also obligated to pay us up to $37.5 million in success-based milestone payments upon the achievement of certain annual net sales thresholds, as well as a share of certain revenue received by PellePharm in the event that PellePharm sublicenses its rights under the PellePharm Agreement and tiered royalties on annual net sales of Hedgehog Products subject to specified conditions. The remaining milestones have not been recognized as they represent variable consideration that is constrained. In making this assessment, we considered numerous factors, including the fact that achievement of the milestones is outside of our control and contingent upon the future success of clinical trials, PellePharm’s actions, and the receipt of regulatory approval. As the single performance obligation was previously satisfied, all regulatory and commercial-based milestones will be recognized as revenue in full in the period in which the constraint is removed. Any consideration related to sales-based milestone payments, including royalties, will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to PellePharm and therefore are recognized at the later of when the performance obligation is satisfied or the related sales occur. PellePharm is also obligated to pay us tiered royalties on annual net sales of Hedgehog Products, which are subject to reduction after a certain aggregate funding threshold has been achieved. On January 8, 2020, we entered into the BVF Funding Agreement, as further described in Note 9, pursuant to which we sold our interest in all royalty payments based on worldwide annual net sales of the BVF Licensed Product excluding Trailing Mundipharma Royalties related to patidegib. Takeda In July 2010, we entered into a development and license agreement with Intellikine, Inc., or Intellikine, under which we obtained rights to discover, develop and commercialize pharmaceutical products targeting the gamma and/or delta isoforms of PI3K, including eganelisib and duvelisib. In January 2012, Intellikine was acquired by Takeda. In December 2012, we amended and restated our development and license agreement with Takeda and further amended the agreement in July 2014, September 2016, July 2017, and March 2019. We refer to the amended and restated development and license agreement, as amended, as the Takeda Agreement. Duvelisib Pursuant to the Takeda Agreement, prior to March 4, 2019, we were obligated to share equally with Takeda all revenue arising from certain qualifying transactions for duvelisib, including the Secura Bio Agreement, subject to certain exceptions including revenue we receive as reimbursement for duvelisib research and development expenses. On March 4, 2019, we entered into the fourth amendment to the Takeda Agreement, or the Takeda Amendment. Pursuant to the Takeda Amendment, Takeda agreed (i) to the sale of certain royalty payments based on worldwide annual net sales of Licensed Products under the Secura Bio Agreement to HCR, (ii) to forego its rights to an equal share of the royalties due from Secura Bio during the term of the HCR Agreement, and (iii) not to seek any payment from HCR with respect to the royalties owed to Takeda. As consideration for the Takeda Amendment, we paid Takeda $6.7 million representing 25% of the $30.0 million in gross proceeds we received from the closing of the HCR Agreement, net of 25% of the expenses incurred by us in connection with the HCR Agreement. In addition, we agreed to pay Takeda 25% of the royalties that would have been payable to us by Secura Bio but for the consummation of the HCR Agreement, which we refer to as the Interim Obligation. During both the six months ended June 30, 2021 and 2020, we recognized $0.1 million in Interim Obligation amounts owed to Takeda as royalty expense. We have the right to extinguish the Interim Obligation by payment to Takeda of an amount equal to (i) the $6.7 million payment multiplied by a specified multiple corresponding to the time period in which such extinguishing payment is made, minus (ii) any payments made to Takeda pursuant to the Interim Obligation. The Interim Obligation shall expire upon the termination of the HCR Agreement and the reversion of related royalties to us, at which time our obligations to share the royalties payable under the Secura Bio Agreement equally with Takeda shall be reinstated. Eganelisib Pursuant to the Takeda Agreement, we are obligated to pay Takeda up to $3.0 million in remaining success-based development milestone payments and up to $165.0 million in remaining regulatory and commercial-based milestone payments for one product candidate other than duvelisib, which could be eganelisib. |
Stockholders' Equity
Stockholders' Equity | 6 Months Ended |
Jun. 30, 2021 | |
Equity [Abstract] | |
Stockholders' Equity | 12. Stockholders’ Equity Common Stock Sales Facility On June 28, 2019, we entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading, and on July 29, 2019 we amended and restated the sales agreement to add B. Riley Securities (f/k/a B. Riley FBR, Inc.), or B. Riley Securities, as a party to the agreement. On July 27, 2021, we entered into an amendment to the agreement to increase the maximum aggregate offering price of the shares of common stock that we may issue and sell from time to time under the agreement by $75.0 million. We refer to the amended and restated sales agreement, as amended, as the ATM Sales Agreement. As of July 27, 2021, we have an aggregate of $87.1 million available for future sales. Pursuant to the ATM Sales Agreement we may offer and sell shares of our common stock from time to time through JonesTrading or B. Riley Securities, each acting as our sales agent. We have agreed to pay commissions to the sales agents for their services in acting as agents in the sale of our common stock in the amount of up to 3.0% of the gross proceeds from sales of our common stock pursuant to the ATM Sales Agreement. Sales of shares of our common stock under the ATM Sales Agreement may be made by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. With our prior written approval, JonesTrading or B. Riley Securities may also sell the shares by any other method permitted by law, including in negotiated transactions. We and JonesTrading or B. Riley Securities may suspend or terminate the offering of shares upon notice to the other parties and subject to other conditions. During the three and six months ended June 30, 2021 and 2020, we did not sell any shares under the ATM Sales Agreement. Public Offering On February 11, 2021, we entered into a purchase agreement with Piper Sandler & Co., as representative of the underwriters named therein, pursuant to which we issued and sold to the underwriters in an underwritten public offering an aggregate of 24,150,000 shares of our common stock, including 3,150,000 shares of common stock sold in connection with the exercise in full of a 15% over-allotment option by the underwriters. The public offering price was $3.80 per share. The gross proceeds to us from this offering were approximately $91.8 million. After underwriting discounts and commissions and offering expenses, we received net proceeds from the offering of approximately $85.8 million. |
Significant Accounting Polici_2
Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2021 | |
Accounting Policies [Abstract] | |
Basis of Presentation | 2. Basis of Presentation These condensed consolidated financial statements include the accounts of Infinity and its wholly-owned subsidiaries. We have eliminated all significant intercompany accounts and transactions in consolidation. The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the accompanying condensed consolidated financial statements have been included. Interim results for the three and six months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2021. The information presented in the condensed consolidated financial statements and related footnotes at June 30, 2021, and for the three and six months ended June 30, 2021 and 2020, is unaudited, and the condensed consolidated balance sheet amounts and related footnotes at December 31, 2020 have been derived from our audited financial statements. For further information, please refer to the consolidated financial statements and accompanying footnotes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission, or SEC, on March 16, 2021, which we refer to as our 2020 Annual Report on Form 10-K. |
Liquidity | Liquidity As of June 30, 2021, we had cash and cash equivalents of $97.3 million. We have primarily incurred operating losses since inception and have relied on our ability to fund our operations through collaboration and license arrangements or other strategic arrangements, as well as through the sale of stock. We expect to continue to spend significant resources to fund the development and potential commercialization of eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma, or PI3K-gamma, and to incur significant operating losses for the foreseeable future. We believe that our existing cash and cash equivalents at June 30, 2021 will be adequate to satisfy our forecasted operating needs for at least the next twelve months from the issuance date of these financial statements. |
Segment Information | Segment Information We operate in one business segment, which focuses on drug development. We make operating decisions based upon the performance of the enterprise as a whole and utilize our consolidated financial statements for decision making. |
Basic and Diluted Net Loss per Common Share | Basic and Diluted Net Loss per Common ShareBasic net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted net loss per share is based upon the weighted average number of common shares outstanding during the period plus the effect of additional weighted average common equivalent shares outstanding during the period when the effect of adding such shares is dilutive. Common equivalent shares result from the assumed exercise of outstanding stock options and the exercise of outstanding warrants (the proceeds of which are then assumed to have been used to repurchase outstanding stock using the treasury stock method). In addition, the assumed proceeds under the treasury stock method include the average unrecognized compensation expense of stock options that are in-the-money. This results in the “assumed” buyback of additional shares, thereby reducing the dilutive impact of stock options. The two-class method is used for outstanding warrants as such warrants are considered to be participating securities, and this method is more dilutive than the treasury stock method. |
New Accounting Pronouncements | New Accounting Pronouncements In June 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standard Update, or ASU, No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements, or ASU No. 2016-13, which requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and it establishes additional disclosure requirements related to credit risks. For available-for-sale debt securities with expected credit losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. In November 2019, the FASB subsequently issued ASU 2019-10, Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates, whereby the effective date of this standard for smaller reporting companies was deferred to annual reporting periods beginning after December 15, 2022, including interim periods within those annual reporting periods, and early adoption is still permitted. We are currently evaluating the impact of ASU No. 2016-13 on our consolidated financial statements and related disclosures. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, or ASU No. 2020-06, which simplifies the guidance on an issuer’s accounting for convertible instruments and contracts in its own equity. The provisions of ASU No. 2020-06 are applicable for fiscal years beginning after December 15, 2023, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. We are currently evaluating the impact of ASU No. 2020-06 on our consolidated financial statements. |
Significant Accounting Polici_3
Significant Accounting Policies (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Accounting Policies [Abstract] | |
Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share | The following outstanding shares of common stock equivalents were excluded from the computation of net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: At June 30, 2021 2020 Stock options 12,583,847 11,108,447 Warrants (excluded from treasury stock method) — 1,000,000 |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Stock-Based Compensation Expense, Related to All Equity Awards | Total stock-based compensation expense related to all equity awards for the three and six months ended June 30, 2021 and 2020 was composed of the following: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 (in thousands) Research and development $ 165 $ 94 $ 316 $ 174 General and administrative 507 266 886 546 Total stock-based compensation expense $ 672 $ 360 $ 1,202 $ 720 |
Black-Scholes Valuation Model, Weighted-Average Assumptions for Stock Options | For the three and six months ended June 30, 2021 and 2020, the fair values were estimated using the Black-Scholes valuation model using the following weighted-average assumptions: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Risk-free interest rate 0.8 % 0.3 % 0.9 % 1.4 % Expected annual dividend yield — — — — Expected stock price volatility 106.5 % 101.6 % 105.5 % 98.2 % Expected term of options 5.5 years 4.1 years 5.6 years 5.6 years |
Cash, Cash Equivalents and Av_2
Cash, Cash Equivalents and Available-for-Sale Securities (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Cash and Cash Equivalents [Abstract] | |
Summary of Cash, Cash Equivalents and Available-for-sale Securities | The following is a summary of cash, cash equivalents and available-for-sale securities: June 30, 2021 Cost Gross Gross Estimated (in thousands) Cash and cash equivalents $ 97,258 $ — $ — $ 97,258 Total cash and cash equivalents $ 97,258 $ — $ — $ 97,258 December 31, 2020 Cost Gross Gross Estimated (in thousands) Cash and cash equivalents $ 28,593 $ — $ — $ 28,593 Available-for-sale securities: U.S. Treasury securities due in one year or less 5,516 — (1) 5,515 Total available-for-sale securities 5,516 — (1) 5,515 Total cash, cash equivalents and available-for-sale securities $ 34,109 $ — $ (1) $ 34,108 |
Fair Value (Tables)
Fair Value (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value, Assets Measured on Recurring Basis | The following table presents the assets and liabilities carried at fair value measured on a recurring basis as of June 30, 2021 and December 31, 2020: June 30, 2021 Level 1 Level 2 Level 3 (in thousands) Assets: Cash and cash equivalents $ 97,258 $ — $ — Total assets $ 97,258 $ — $ — Liabilities: Warrant liability $ — $ — $ 185 Total liabilities $ — $ — $ 185 December 31, 2020 Level 1 Level 2 Level 3 (in thousands) Assets: Cash and cash equivalents $ 28,593 $ — $ — U.S. Treasury securities — 5,515 — Total assets $ 28,593 $ 5,515 $ — Liabilities: Warrant liability $ — $ — $ 198 Total liabilities $ — $ — $ 198 |
Prepaid Expenses and Other Cu_2
Prepaid Expenses and Other Current Assets (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |
Schedule of Prepaid Expenses and Other Current Assets | Prepaid expenses and other current assets consisted of the following: June 30, 2021 December 31, 2020 (in thousands) Prepaid expenses $ 2,026 $ 1,528 Restricted cash, current portion 150 150 Other current assets 243 234 Total prepaid expenses and other current assets $ 2,419 $ 1,912 |
Accrued Expenses and Other Cu_2
Accrued Expenses and Other Current Liabilities (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Payables and Accruals [Abstract] | |
Schedule of Accrued Expenses | Accrued expenses and other current liabilities consisted of the following: June 30, 2021 December 31, 2020 (in thousands) Accrued clinical and development $ 5,404 $ 3,511 Accrued compensation and benefits 1,667 2,385 Liability related to sale of future royalties, net, current portion 917 848 Operating lease liability, current portion 500 489 Other 1,112 832 Total accrued expenses $ 9,600 $ 8,065 |
Liabilities Related to Sale o_2
Liabilities Related to Sale of Future Royalties (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Debt Disclosure [Abstract] | |
Schedule of Liability Related to Future Sale of Royalties | The following table shows the activity within the liability account for the six months ended June 30, 2021: June 30, 2021 (in thousands) Liability related to sale of future royalties, net - beginning balance $ 28,869 Non-cash royalty revenue (518) Non-cash interest expense recognized 77 Liability related to sale of future royalties, net - ending balance 28,428 Less: current portion (917) Liability related to sale of future royalties, net, less current portion $ 27,511 The following table shows the activity within the liability account for the six months ended June 30, 2021: June 30, 2021 (in thousands) Liability related to sale of future royalties, net - beginning balance $ 21,559 Non-cash interest expense recognized 13 Liability related to sale of future royalties, net - ending balance $ 21,572 |
Basis of Presentation (Details)
Basis of Presentation (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Cash, cash equivalents, and available-for-sale securities | $ 97,258 | $ 34,108 |
Significant Accounting Polici_4
Significant Accounting Policies - Additional Information (Details) | 6 Months Ended |
Jun. 30, 2021segment | |
Accounting Policies [Abstract] | |
Number of operating segments | 1 |
Significant Accounting Polici_5
Significant Accounting Policies - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Stock options | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share (in shares) | 12,583,847 | 11,108,447 |
Warrants (excluded from treasury stock method) | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share (in shares) | 0 | 1,000,000 |
Stock-Based Compensation - Sche
Stock-Based Compensation - Schedule of Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Total stock-based compensation expense | $ 672 | $ 360 | $ 1,202 | $ 720 |
Research and development | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Total stock-based compensation expense | 165 | 94 | 316 | 174 |
General and administrative | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Total stock-based compensation expense | $ 507 | $ 266 | $ 886 | $ 546 |
Stock-Based Compensation - Addi
Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Share-based Payment Arrangement [Abstract] | ||
Unrecognized compensation cost, net of estimated forfeitures, related to unvested stock options | $ 5.1 | |
Unrecognized compensation cost, weighted-average recognition period, stock options | 2 years 9 months 18 days | |
Stock options granted (in shares) | 289,040 | 3,148,786 |
Stock options granted, weighted average fair value (in dollars per share) | $ 2.68 | $ 0.89 |
Stock options granted, weighted average exercise price (in dollars per share) | $ 3.37 | $ 1.17 |
Stock-Based Compensation - Stoc
Stock-Based Compensation - Stock Options (Details) - Stock options | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Risk-free interest rate | 0.80% | 0.30% | 0.90% | 1.40% |
Expected annual dividend yield | 0.00% | 0.00% | 0.00% | 0.00% |
Expected stock price volatility | 106.50% | 101.60% | 105.50% | 98.20% |
Expected term of options | 5 years 6 months | 4 years 1 month 6 days | 5 years 7 months 6 days | 5 years 7 months 6 days |
Cash, Cash Equivalents and Av_3
Cash, Cash Equivalents and Available-for-Sale Securities - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 | Jun. 30, 2020 |
Debt Securities, Available-for-sale [Line Items] | |||
Cash and cash equivalents, cost | $ 97,258 | $ 28,593 | $ 28,921 |
Cash and cash equivalents, gross unrealized gains | 0 | 0 | |
Cash and cash equivalents, gross unrealized losses | 0 | 0 | |
Cash and cash equivalents, estimated fair value | 97,258 | 28,593 | |
Total available-for-sale securities | 5,516 | ||
Total available-for-sale securities, gross unrealized gains | 0 | ||
Total available-for-sale securities, gross unrealized losses | (1) | ||
Total available-for-sale securities, estimated fair value | 5,515 | ||
Total cash and cash equivalents and available-for-sale securities, at cost | 97,258 | 34,109 | |
Total cash, cash equivalents and available-for-sale securities, gross unrealized gains | 0 | 0 | |
Total cash, cash equivalents and available-for-sale securities, gross unrealized losses | 0 | (1) | |
Total cash, cash equivalents and available-for-sale securities, estimated fair value | $ 97,258 | 34,108 | |
U.S. Treasury securities due in one year or less | |||
Debt Securities, Available-for-sale [Line Items] | |||
Available-for-sale securities | 5,516 | ||
Available-for-sale securities, gross unrealized gains | 0 | ||
Available-for-sale securities, gross unrealized losses | (1) | ||
Available-for-sale securities, estimated fair value | $ 5,515 |
Cash, Cash Equivalents and Av_4
Cash, Cash Equivalents and Available-for-Sale Securities - Additional Information (Details) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021USD ($)security | Jun. 30, 2020USD ($) | Jun. 30, 2021USD ($)security | Jun. 30, 2020USD ($) | |
Cash and Cash Equivalents [Abstract] | ||||
Debt securities, unrealized loss position, number | security | 0 | 0 | ||
Available-for-sale securities, material realized gains or losses | $ 0 | $ 0 | $ 0 | $ 0 |
Available-for-sale securities, other-than-temporary impairments | $ 0 | $ 0 | $ 0 | $ 0 |
Fair Value - Schedule of Assets
Fair Value - Schedule of Assets Recurring Basis (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | $ 97,258 | $ 28,593 |
U.S. Treasury securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
U.S. Treasury securities | 5,515 | |
Fair Value, Measurements, Recurring | Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | 97,258 | 28,593 |
Total assets | 97,258 | 28,593 |
Warrant liability | 0 | 0 |
Total liabilities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 1 | U.S. Treasury securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
U.S. Treasury securities | 0 | |
Fair Value, Measurements, Recurring | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | 0 | 0 |
Total assets | 0 | 5,515 |
Warrant liability | 0 | 0 |
Total liabilities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 2 | U.S. Treasury securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
U.S. Treasury securities | 5,515 | |
Fair Value, Measurements, Recurring | Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | 0 | 0 |
Total assets | 0 | 0 |
Warrant liability | 185 | 198 |
Total liabilities | $ 185 | 198 |
Fair Value, Measurements, Recurring | Level 3 | U.S. Treasury securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
U.S. Treasury securities | $ 0 |
Fair Value - Additional Informa
Fair Value - Additional Information (Details) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Available-for-sale securities | $ 5,515,000 | |
Level 3 | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Available-for-sale securities | $ 0 | $ 0 |
Prepaid Expenses and Other Cu_3
Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 | Jun. 30, 2020 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |||
Prepaid expenses | $ 2,026 | $ 1,528 | |
Restricted cash, current portion | 150 | 150 | $ 0 |
Other current assets | 243 | 234 | |
Total prepaid expenses and other current assets | $ 2,419 | $ 1,912 |
Accrued Expenses and Other Cu_3
Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Payables and Accruals [Abstract] | ||
Accrued clinical and development | $ 5,404 | $ 3,511 |
Accrued compensation and benefits | 1,667 | 2,385 |
Liability related to sale of future royalties, net, current portion | 917 | 848 |
Operating lease liability, current portion | 500 | 489 |
Other | 1,112 | 832 |
Total accrued expenses | $ 9,600 | $ 8,065 |
Liabilities Related to Sale o_3
Liabilities Related to Sale of Future Royalties - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions | Jan. 08, 2020 | Mar. 11, 2019 | Jun. 30, 2021 |
Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||
Number of warrants issued (in shares) | 0 | ||
BVF Funding Agreement | |||
Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||
Warrant threshold, price per share (in dollars per share) | $ 3.75 | ||
Infinity Pharmaceuticals | Biotechnology Value Fund, L.P. | |||
Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||
Ownership percentage, noncontrolling interest | 30.00% | ||
Holdco | Infinity Pharmaceuticals | BVF Funding Agreement | |||
Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||
Option to purchase, percentage of outstanding equity interests | 100.00% | ||
HealthCare Royalty Partners III, L.P. | |||
Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||
Closing day payment | $ 30 | ||
Deferred transaction costs amortized | $ 2.4 | ||
BVF And Royalty Security, LLC | BVF Funding Agreement | |||
Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||
Deferred transaction costs amortized | $ 0.4 | ||
Upfront purchase price | 20 | ||
Warrant liability | $ 0.3 | ||
Period after closing date | 36 months | ||
Percentage of common stock called by warrant | 50.00% | ||
Exercise price of warrant, percentage of price per share | 150.00% |
Liabilities Related to Sale o_4
Liabilities Related to Sale of Future Royalties - Liability Activity (Details) - USD ($) $ in Thousands | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | |
Liability Related To Future Sale Of Royalties [Roll Forward] | |||
Non-cash royalty revenue | $ (518) | $ (417) | |
Non-cash interest expense recognized | 90 | $ 77 | |
Less: current portion | (917) | $ (848) | |
Liability related to sale of future royalties, net, less current portion | 49,083 | $ 28,021 | |
HCR Agreement | |||
Liability Related To Future Sale Of Royalties [Roll Forward] | |||
Liability related to sale of future royalties, net - beginning balance | 28,869 | ||
Non-cash royalty revenue | (518) | ||
Non-cash interest expense recognized | 77 | ||
Liability related to sale of future royalties, net - ending balance | 28,428 | ||
Less: current portion | (917) | ||
Liability related to sale of future royalties, net, less current portion | 27,511 | ||
BVF Funding Agreement | |||
Liability Related To Future Sale Of Royalties [Roll Forward] | |||
Liability related to sale of future royalties, net - beginning balance | 21,559 | ||
Non-cash interest expense recognized | 13 | ||
Liability related to sale of future royalties, net - ending balance | $ 21,572 |
Commitments and Contingencies (
Commitments and Contingencies (Details) | 12 Months Ended | 48 Months Ended | ||
Jul. 31, 2020USD ($) | Aug. 01, 2024 | Jun. 30, 2021USD ($) | Apr. 03, 2019USD ($)ft² | |
Leases Of Lessee Disclosure [Line Items] | ||||
Total future minimum lease payments | $ 2,000,000 | |||
1100 Massachusetts Avenue, Cambridge, Massachusetts | ||||
Leases Of Lessee Disclosure [Line Items] | ||||
Area of premises leased under lease agreement | ft² | 10,097 | |||
Lease term | 5 years | |||
Monthly base rent expense | $ 47,961 | |||
Restricted cash, bank fee | $ 15,000 | |||
Leasehold improvements | $ 600,000 | |||
1100 Massachusetts Avenue, Cambridge, Massachusetts | Forecast | ||||
Leases Of Lessee Disclosure [Line Items] | ||||
Annual percentage increase of rent expense | 3.00% | |||
Letter of Credit | 1100 Massachusetts Avenue, Cambridge, Massachusetts | ||||
Leases Of Lessee Disclosure [Line Items] | ||||
Security deposit | 300,000 | |||
Security deposit, reduced amount under lease term | $ 150,000 |
Strategic Agreements - Addition
Strategic Agreements - Additional Information (Details) $ in Thousands | Mar. 11, 2019USD ($) | Mar. 04, 2019USD ($) | Jun. 30, 2013USD ($) | Jun. 30, 2021USD ($) | Jun. 30, 2020USD ($) | Jun. 30, 2021USD ($)product | Jun. 30, 2020USD ($) |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||
Royalty expense (note 11) | $ 308 | $ 217 | $ 590 | $ 475 | |||
Number of distinct product candidates | product | 1 | ||||||
Trailing Mundipharma | |||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||
Royalty percentage on sales. reimbursement of research and development, percentage | 4.00% | ||||||
Royalty payments, reimbursement of research and development upon completion | $ 260,000 | ||||||
Royalty percentage on sales, reimbursement of research and development upon completion, percentage | 1.00% | ||||||
PellePharm Agreement | Hedgehog Products | |||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||
Collaborative agreement, total remaining milestone payment amount | $ 9,000 | ||||||
Collaborative agreement, additional milestone payments amount, if circumstances met | $ 37,500 | ||||||
Takeda | Takeda Agreement, Fourth Amendment | |||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||
Investment amount to be paid | $ 6,700 | ||||||
Percentage of investment amount | 25.00% | ||||||
Percentage of net expenses incurred | 25.00% | ||||||
Percentage of royalty payments | 25.00% | ||||||
Royalty expense (note 11) | $ 100 | $ 100 | |||||
HealthCare Royalty Partners III, L.P. | |||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||
Closing day payment | $ 30,000 | ||||||
Maximum | |||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||
Additional success-based milestone payments to be paid | 165,000 | 165,000 | |||||
Maximum | Current | |||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||
Success-based remaining milestone payments | $ 3,000 | $ 3,000 |
Stockholders' Equity (Details)
Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Millions | Jul. 27, 2021 | Feb. 11, 2021 | Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 |
Subsidiary, Sale of Stock [Line Items] | ||||||
Number of shares sold in transaction (in shares) | 24,150,000 | 0 | 0 | 0 | 0 | |
Sale of stock, over-allotment option | 15.00% | |||||
Shares sold, price per share (in dollars per share) | $ 3.80 | |||||
Gross proceeds from shares sold | $ 91.8 | |||||
Net proceeds from shares sold | $ 85.8 | |||||
Subsequent Event | ||||||
Subsidiary, Sale of Stock [Line Items] | ||||||
Sales agreement, increase in aggregate offering price | $ 75 | |||||
Amount available for future sales | $ 87.1 | |||||
Sales agreement, commission percentage | 3.00% | |||||
Over-Allotment Option | ||||||
Subsidiary, Sale of Stock [Line Items] | ||||||
Number of shares sold in transaction (in shares) | 3,150,000 |